What Physicians Want Patients to Know About the 2025–2026 Respiratory Virus Season

Key takeaway: COVID-19, influenza (flu), and respiratory syncytial virus (RSV) continue to circulate nationwide. Updated CDC guidance for the 2025–2026 respiratory virus season emphasizes vaccination for eligible groups, early testing for high-risk patients, and prompt treatment when appropriate.

As a public health writer, I look to federal health agencies and peer-reviewed evidence first. This season’s guidance from the Centers for Disease Control and Prevention (CDC) focuses less on emergency response and more on practical prevention—especially for older adults, young children, pregnant people, and those with chronic medical conditions.

What’s Circulating Now

According to the CDC, the three major respiratory viruses driving most seasonal illness in the United States remain:

Influenza (flu)
COVID-19
Respiratory syncytial virus (RSV)

These viruses spread mainly through respiratory droplets and close contact. Symptoms often overlap, which can make it hard to tell them apart without testing.

Common symptoms

Fever or chills
Cough
Sore throat
Runny or stuffy nose
Fatigue
Muscle or body aches
Shortness of breath (more common with COVID-19 or severe flu)

RSV in infants may present with wheezing, feeding difficulty, or increased work of breathing. In older adults, RSV can worsen heart or lung disease.

Vaccination: Who Should Consider It

The CDC continues to recommend seasonal flu vaccination for everyone 6 months and older, unless contraindicated. Updated COVID-19 vaccines are recommended for eligible age groups, particularly older adults and people with weakened immune systems. RSV immunization strategies now include:

Maternal RSV vaccination during pregnancy to protect newborns
Long-acting monoclonal antibody protection for eligible infants
RSV vaccines for adults 60 and older, based on shared clinical decision-making or age-based recommendations depending on product labeling

Guidance on RSV vaccines and monoclonal antibodies has evolved in recent seasons following FDA approvals and CDC advisory committee recommendations. Patients should speak with their clinician about eligibility, especially if they are over 60, pregnant, or caring for a newborn.

Who Is at Higher Risk for Severe Illness?

Across all three viruses, the highest-risk groups generally include:

Adults 65 and older
Infants, especially under 6 months
Pregnant and recently pregnant people
People with chronic conditions (heart disease, lung disease, diabetes, kidney disease)
Immunocompromised individuals
Residents of nursing homes or long-term care facilities

For these groups, early testing and timely treatment can reduce complications. Antiviral medications for flu and COVID-19 are most effective when started early, typically within the first few days of symptoms.

Testing and Treatment: Timing Matters

Because symptoms overlap, clinicians may recommend testing—especially for high-risk patients. According to CDC guidance:

Flu antivirals (such as oseltamivir) can reduce severity and duration if started early.
COVID-19 antiviral treatments are available for eligible high-risk patients.
RSV treatment is mainly supportive in most cases, though prevention strategies are now available for specific populations.

Testing may also influence decisions about isolation, masking in healthcare settings, and protecting vulnerable family members.

Prevention Still Matters in Everyday Settings

Public health recommendations now emphasize layered prevention rather than universal mandates. Practical steps include:

Staying up to date on recommended vaccines
Staying home when sick
Improving indoor ventilation when possible
Washing hands regularly
Wearing a well-fitting mask in high-risk settings if you or a household member is vulnerable

For families, that may mean keeping a sick child home from school or daycare. For workplaces, it may mean flexible sick policies that reduce spread. For caregivers, it may mean testing before visiting an older relative.

Access and Insurance Considerations

Most private insurance plans and Medicare cover recommended flu and COVID-19 vaccines without cost-sharing when provided by in-network clinicians. RSV vaccine coverage varies by plan and age group, so patients may want to confirm benefits in advance. Medicaid coverage policies can differ by state.

Community health centers and local health departments often provide low- or no-cost vaccination options.

What We Still Don’t Know

Respiratory virus seasons can vary in timing and severity. Strain dominance for influenza shifts from year to year. COVID-19 variants continue to evolve, and vaccine effectiveness may differ depending on how closely vaccine strains match circulating viruses.

Public health agencies update guidance as surveillance data changes. That’s why checking CDC updates during peak season remains important.

Oral Health and Whole-Person Health

Respiratory infections can affect more than the lungs. Severe illness may worsen underlying conditions, including cardiovascular disease. Good oral hygiene does not prevent viral infection, but maintaining overall health—including dental health—supports immune function and reduces complications linked to chronic inflammation.

What This Means for Readers

If you or a family member is at higher risk, consider reviewing vaccination status now rather than waiting for local case counts to rise. If you develop flu-like symptoms and are in a high-risk group, contact a clinician early to ask whether testing or antiviral treatment is appropriate.

For most healthy adults, these viruses will cause a self-limited illness. But for vulnerable individuals, early action can make a meaningful difference.

This article is for general informational purposes only and is not medical advice. Research findings can be early, limited, or subject to change as new evidence emerges. For personal guidance, diagnosis, or treatment, consult a licensed clinician. For current outbreak or public health guidance, follow your local health department, the CDC, or another relevant public health authority.

Sources

Centers for Disease Control and Prevention (CDC) – Respiratory Virus Guidance and Seasonal Vaccine Recommendations
U.S. Food and Drug Administration (FDA) – RSV Vaccine and Antiviral Approvals
National Institutes of Health (NIH) – Respiratory Virus Treatment and Prevention Research Updates